Introduction: Vernal keratoconjunctivitis (VKC) is a chronic, recurrent, bilateral inflammatory disease showing exacerbations during the spring and summer seasons, affecting young children. Present study was conducted with the aim of comparing the efficacy of cyclosporine 0.05% with olopatadine 0.1% in recalcitrant patients of VKC.
INTRODUCTION
Vernal keratoconjunctivitis (VKC) is a chronic, recurrent, bilateral inflammatory disease of cornea and conjunctiva affecting young children, mostly in their first decade of life. 1 Signs and symptoms of VKC show exacerbations during spring and summer seasons, but a small percentage of patients have the perennial form. 2 Diagnosis of this allergic condition is done by the presence of characteristic clinical features which consist of itching, tearing, mucous discharge, conjunctival hyperemia, cobblestone papillae seen over upper tarsal conjunctiva, Tranta's spots over the limbus, and superficial keratitis. Severe corneal involvements in the form of shield ulceration and conjunctival cicatrization are sight threatening.
The pathogenesis of VKC is considered to be multifocal with the involvement of immune, nervous, and endocrine systems. [3] [4] [5] Steroids are being used as the mainstay of treatment for VKC, but a standard treatment protocol is not yet established. Steroids are very effective in controlling the acute exacerbation, but they may cause intraocular pressure elevation in steroid-responders, risk of corneal infection, and cataract. Therefore, they are used for a short period of time. 6 Topical mast cell stabilizers and antihistaminics are also used to reduce the signs and symptoms of the disease. Olopatadine 0.1% acts as a mast cell stabilizer as well as an antihistaminic in treating patients of VKC. Studies have shown that it is more effective than sodium cromoglycate, ketorolac, and levocabastine. [7] [8] [9] Cyclosporine 0.05% is a nonsteroidal immunomodulator, used as an effective alternative for the control of ocular inflammation. It inhibits eosinophilic infiltration into the conjunctiva without affecting systemic immune responses. 10 In the present prospective study, we compared the effects of topical olopatadine 0.1% vs topical cyclosporine 0.05% on the signs and symptoms of patients of recalcitrant VKC, with an aim to earmark the superiority of either of the drugs in the management of VKC. , and fulfilling the inclusion criteria were included in the study. A total of 20 patients (40 eyes) were enrolled in the study. An informed consent was taken from them after which each patient was subjected to a detailed slit lamp examination.
MATERIALS AND METHODS

This
Symptoms like itching, tearing, foreign body sensation, and discharge were graded on a scale of 0 to 3 on the basis of grading system adopted from Ozcan et al 11 (Table 1) .
Signs like limbal hypertrophy, bulbar conjunctival hyperemia, and tarsal conjunctival hypertrophy were noted and graded on a scale of 0 to 3. Grading system is shown in Table 2 .
After grading of signs and symptoms, treatment was initiated. All patients received a short course of topical fluorometholone thrice daily, in both eyes for a period of 5 days. Along with this, right eye of each patient received topical olopatadine 0.1%, twice a day and left eye of same patient received topical cyclosporine 0.05% (Imudrops), twice daily. Patients were followed up for a period of 3 months, and scoring of signs and symptoms was done at 2 weeks, 1 month, and 3 months intervals.
Statistical Analysis
Statistical analysis of data was done using Statistical Package for the Social Sciences software version 22.0 and unpaired t-test was applied. A p-value of <0.05 was considered statistically significant.
RESULTS
The present study was done on 40 eyes of 20 patients of VKC in whom majority were male (70%) as compared with females (30%).
Mean age of the patients was 9.4 years, with minimum and maximum age being 7 and 14 years respectively.
Mean scores for signs and symptoms of both olopatadine-treated eyes and cyclosporine-treated eyes are given in Table 3 . At 2 weeks posttreatment, olopatadine-treated eyes showed a significant reduction in mean symptom score (p < 0.01). Similarly, in cyclosporine-treated eyes, a highly significant reduction was seen (p < 0.001). Both drugs were individually effective in lowering the mean symptom and sign score posttreatment at 1 and 3 months intervals when compared with mean baseline symptom and sign scores.
On comparative analysis of mean symptom and sign score between olopatadine-and cyclosporine-treated eyes, the response noted was not statistically significant at 2 weeks (p > 0.05). At 1 and 3 months, a highly significant difference was noted (p < 0.001) ( Table 4) .
DISCUSSION
Vernal keratoconjunctivitis is a chronic allergic inflammation, which is characterized by recurrent, mostly symmetrical involvement of both eyes. 12 Disease shows seasonal exacerbations, but occasional perennial forms are also encountered. 
IJAIMS
Male pediatric population is typically more affected than female, 1, 5, 13 and similar observation was noted in the present study, with male:female ratio of 2.3:1.
Rarely seen in adults, VKC affects young children in the first decade of life.
14, 15 Leonardi et al 16 conducted a study on 406 VKC patients and reported that 83% of the patients were less than 10 years of age at the time of presentation and same age distribution was seen in this study. Vernal keratoconjunctivitis is a multifactorial disease with immune-mediated processes. T-helper 2 (Th2) lymphocytes, eosinophils, immunoglobulin E (IgE), mast cells, interleukins, and other cell mediators are known to play a major role. 11 Few authors have reported that neural factors and sex hormones also contribute to the pathogenesis of VKC.
3,12,14
As for other allergic conditions, the main aim of treatment in VKC is blockage of release of allergic mediators and control of allergic inflammatory cascade and, in turn, protection of ocular structures. Various treatment modalities of VKC are topical mast cell stabilizers, antihistaminics, corticosteroids, and immunomodulators.
Cyclosporine is an immunomodulator, which acts as an anti-inflammatory agent by blocking histamine release from mast cells through inhibition of calcineurin essential for IgE receptor mediated exocytosis of preformed mediators from mast cells. It also acts by inhibiting Th2 lymphocyte proliferation and interleukin (IL)-2 and IL-5 production and, thus, prevents eosinophil infiltration. 17 Various studies have reported the benefit of cyclosporine in reducing the ocular signs and symptoms in patients of VKC with different grades of severity. [18] [19] [20] [21] In the present study, a comparison of efficacy of both cyclosporine and olopatadine with regard to objective symptoms like itching, tearing, foreign body sensation, discharge, and signs like limbal hypertrophy, hyperemia of bulbar conjunctiva, and papillary hypertrophy over the palpebral conjunctiva was done.
A significant improvement in symptoms and signs was noted at 2 weeks in eyes treated with cyclosporine as well as those treated with olopatadine, but the results were highly significant in the eyes treated with cyclosporine.
At 2 weeks, when we compared both, no statistically significant results were seen. Then after a period of 1 month, improvement in the cyclosporine eyes was statistically significant with a p < 0.01 for symptoms and p < 0.01 for signs. After 3-month interval, highly significant difference was noted in the cyclosporine-treated eyes for both symptoms and signs (p < 0.001).
Limitations of the study were a small sample size and a short follow-up period. Further studies are required to establish the efficacy of cyclosporine as a prophylactic measure for the acute exacerbations in patients of recalcitrant VKC.
CONCLUSION
In early phase of the treatment, both cyclosporine 0.05% and olopatadine 0.1% were found to be equally effective 
